Aim: To develop and characterize mesalamine-loaded nanoparticles for enhanced efficacy and targeted delivery in the treatment of ulcerative colitis (UC), addressing the limitations of conventional mesalamine therapies. Methodology: Mesalamine nanoparticles were formulated using the solvent evaporation technique and optimized for particle size, morphology, drug loading efficiency, and release kinetics. Dynamic light scattering (DLS), scanning electron microscopy (SEM), and Fourier-transform infrared spectroscopy (FTIR) were employed for comprehensive characterization. In vitro drug release studies assessed the sustained release profile, and pharmacokinetic studies evaluated the nanoparticles__ampersandsignrsquo; localized drug delivery potential to inflamed colonic tissues. Results: The formulated mesalamine nanoparticles exhibited a mean particle size of 150 __ampersandsignplusmn; 20 nm with a narrow size distribution and a high drug loading capacity of 85 __ampersandsignplusmn; 5%. DLS and SEM analyses confirmed uniform morphology and particle stability, while FTIR verified successful drug encapsulation. In vitro studies demonstrated a sustained mesalamine release over an extended period, outperforming conventional formulations. Pharmacokinetic studies further revealed enhanced localization and prolonged drug availability in inflamed tissues, indicating improved therapeutic efficacy. Conclusion: Mesalamine-loaded nanoparticles offer a promising drug delivery system for ulcerative colitis, significantly enhancing bioavailability and targeted delivery. This novel approach could overcome the limitations of traditional therapies, providing more effective management of UC and improving patient outcomes.